Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Sponsored by Exelixis Pharmaceuticals, Incorporated
Active
$494.2K Funding
6 People
External
Related Topics
cancer,
immunotherapy,
clinical trials,
metastasis,
treatment comparison
People
Brianna Loughran
(CD)
Cancer Center Division
﹒Clinical Research Coordinator II
Rachna Shroff
Co-Investigator (COI)
Medicine
﹒Professor
Bryan Clines
(CD)
Cancer Center Division
﹒Research Compliance Administrator III
Brianna Denton
(CD)
Cancer Center Division
﹒Research Compliance Manager I
Diana Dawson
(CD)
Cancer Center Division
﹒Research Compliance Administrator II
Hina Arif Tiwari
Co-Investigator (COI)
Pathology and Lab Medicine
﹒Professor
